A plausible strategy for investing in biotechs is to find those companies that have recently gone public and that are practising good science and business, but which have been beaten down due to the selling -- real or anticipated -- of insiders when the lock-up periods expire. Given the huge financing bubble in 2000, there are many targets to screen.
This thread is dedicated to finding the overly punished, and a portfolio will be assembled based on contributors' picks and polite discussion thereof.
If the unlock is large, best to swing or position trade these babies. And why not short those doomed to fall while we're at it? If the unlock isn't too bad, or has already been worked through somewhat, maybe buy and hold for a while.
Cheers, Tuck |
